4.7 Article

Novel missense and truncating mutations in FUS/TLS in familial ALS

Journal

NEUROLOGY
Volume 75, Issue 9, Pages 815-817

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181f07e26

Keywords

-

Funding

  1. German Federal Ministry of Education and Research [01GI0704]
  2. Stavros-Niarchos Foundation
  3. Synapsis Foundation
  4. Air Berlin Fonds for ALS Research
  5. Teva Pharmaceutical Industries Ltd.
  6. Lundbeck Inc.
  7. Boehringer Ingelheim
  8. Sanofi-Aventis
  9. Ono Pharmaceutical Co. Ltd.
  10. Santhera Pharmaceuticals
  11. Knopp Neurosciences Inc.
  12. Schwarz Pharma
  13. GlaxoSmithKline
  14. Bayer Schering Pharma
  15. Fresenius Medical Care
  16. Trophos SA
  17. Takeda Pharmaceutical Company Limited
  18. Deutsche Forschungsgemeinschaft (DFG)
  19. Packard Foundation

Ask authors/readers for more resources

Background: Mutations in the FUS/TLS gene have been associated with familial amyotrophic lateral sclerosis (FALS). Methods: We analyzed the presence and frequency of C-terminal FUS/TLS mutations in a German amyotrophic lateral sclerosis (ALS) cohort, including 133 patients with sporadic ALS (SALS) and 58 patients with FALS by sequence analysis of exons 13-15. Results: We identified 2 novel heterozygous FUS/TLS mutations in 4 German ALS families including the novel missense mutation K510R and the truncating mutation R495X. The truncating mutation was associated with an aggressive disease course whereas the K510R mutation showed a mild phenotype with disease duration ranging from 6 to 8 years. No mutation was detected in 133 patients with SALS. Conclusions: Mutations in FUS/TLS account for 7% (4 of 58) of FALS in our German cohort. Neurology (R) 2010;75:815-817

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available